New York : Monsanto Co, the world’s largest seed company, will reject Bayer AG’s $62 billion acquisition bid and seek a higher price, two people familiar with the matter said on Tuesday.
Monsanto can see the logic of combining with the German drugs and crop chemicals group, and believes a deal could get the necessary antitrust and other regulatory approvals, the people said, leaving the door open for further negotiations.
Bayer will now have to decide whether to raise its bid, even as the company faces criticism from some shareholders that its $122 per share offer is already too high. The other options are to walk away, or mount a hostile bid.
Monsanto shares rose 1.5% to $107.61 in late morning trading in New York, but remain far below Bayer’s bid price, underscoring investor skepticism that a deal will be reached. Bayer shares rose 3.23% at 87.15 euros in Frankfurt.
Monsanto and Bayer declined to comment. It was not clear what price Monsanto would be willing to sell for.
The Saint Louis, Missouri-based company has confidence in its standalone plan and believes shareholders deserve a better offer, the people said. They asked not to be identified because the deliberations are confidential.
Global agro-chemicals companies are racing to consolidate, partly in response to a drop in commodity prices that has hit farm incomes.
Seeds and pesticides markets are also increasingly converging.
Latest posts by savita thakur (see all)
- 2000 medicines to become up to 90 percent cheaper: Nadda - November 7, 2016
- Drugmakers under fire for possible US price fixing - November 7, 2016
- Pharma cos see huge sell off: Sun Pharma, Dr Reddys hit hard - November 7, 2016